A Phase 3 interventional study of Tirzepatide and Insulin Glargine in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 67 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-06.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 14th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 917 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 31st largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2019, is one of 85 in phase 3, and was the 154th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
Drug: Tirzepatide
Participants received 10 mg tirzepatide administered SC QW.
Drug: Tirzepatide
Participants received 15 mg tirzepatide administered SC QW.
Drug: Tirzepatide
Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.
Drug: Insulin Glargine
Administered SC
Also known as: LY3298176
Administered SC
Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with covariates Baseline + Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus Sulfonylurea (SU)) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 40
Mean Change From Baseline in HbA1c (5 mg)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 40
Mean Change From Baseline in Body Weight
LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.
Time frame: Baseline, Week 40
Percentage of Participants Achieving an HbA1c Target Value of <7.0%
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
Time frame: Week 40
Percentage of Participants Achieving an HbA1c Target Value of <5.7%
HbA1c is the glycosylated fraction of hemoglobin A. Imputed data includes observed value and imputed value if endpoint measure is missing.
Time frame: Week 40
Mean Change From Baseline in Fasting Serum Glucose
Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.
Time frame: Baseline, Week 40
Mean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
The SMBG data was collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post-meal, Midday Premeal, Midday 2-hour Post-meal, Evening Premeal, Evening 2-hour Post-meal and Bedtime. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.
Time frame: Baseline, Week 40
Percentage of Participants Who Achieved Weight Loss ≥5%
Imputed data includes observed value and imputed value if endpoint measure is missing.
Time frame: Week 40
Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score
DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The treatment satisfaction score ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS mean was determined by ANCOVA model for endpoint measures with Baseline + Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Baseline OAM Use (Met, Met plus SU) + Treatment (Type III sum of squares) as covariates.
Time frame: Baseline, Week 40
Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia
The hypoglycemia events were defined by participant reported events with blood glucose \< 54 mg/dL \[\<3.0 Millimole per Liter (mmol/L)\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of post-baseline hypoglycemia was estimated by negative binomial model: Number of episodes = Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment, with log (exposure in days/365.25) as an offset variable.
Time frame: Baseline through end of safety follow-up (Up To Week 44)
| Milestone | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Started | 230 | 228 | 229 | 230 |
| Received at least one dose of study drug | 230 | 228 | 229 | 220 |
| Completed | 213 | 201 | 200 | 201 |
| Not completed | 17 | 27 | 29 | 29 |
| Withdrew: Adverse event | 7 | 19 | 18 | 4 |
| Withdrew: Withdrawal by subject | 6 | 6 | 8 | 20 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 2 |
| Withdrew: Participant could not continue due to work related reasons | 0 | 1 | 0 | 1 |
| Withdrew: Covid 19 | 0 | 0 | 0 | 1 |
| Withdrew: Participant thought there were too many adverse events | 0 | 0 | 1 | 0 |
| Withdrew: Participant was reluctant to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Participant did not come for the visit | 1 | 0 | 0 | 0 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with covariates Baseline + Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus Sulfonylurea (SU)) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percentage of HbA1c | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|
| Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) | -2.44 ± 0.073 | -2.49 ± 0.072 | -0.95 ± 0.073 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percentage of HbA1c | 5 mg Tirzepatide | Insulin Glargine |
|---|---|---|
| Mean Change From Baseline in HbA1c (5 mg) | -2.24 ± 0.070 | -0.95 ± 0.073 |
LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.
| kilograms (kg) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Mean Change From Baseline in Body Weight | -5.0 ± 0.32 | -7.0 ± 0.33 | -7.2 ± 0.33 | 1.5 ± 0.33 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Percentage of Participants Achieving an HbA1c Target Value of <7.0% | 75.44 | 86.04 | 84.38 | 23.72 |
HbA1c is the glycosylated fraction of hemoglobin A. Imputed data includes observed value and imputed value if endpoint measure is missing.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Percentage of Participants Achieving an HbA1c Target Value of <5.7% | 14.91 | 20.72 | 27.68 | 0.00 |
Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.
| milligrams per deciliter (mg/dL) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Mean Change From Baseline in Fasting Serum Glucose | -58.6 ± 2.13 | -66.2 ± 2.19 | -64.8 ± 2.19 | -46.2 ± 2.19 |
The SMBG data was collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post-meal, Midday Premeal, Midday 2-hour Post-meal, Evening Premeal, Evening 2-hour Post-meal and Bedtime. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.
| milligrams per deciliter (mg/dL) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Mean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values | -77.0 ± 2.09 | -83.4 ± 2.16 | -84.6 ± 2.18 | -42.8 ± 2.18 |
Imputed data includes observed value and imputed value if endpoint measure is missing.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss ≥5% | 55.70 | 71.62 | 74.11 | 5.58 |
DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The treatment satisfaction score ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS mean was determined by ANCOVA model for endpoint measures with Baseline + Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Baseline OAM Use (Met, Met plus SU) + Treatment (Type III sum of squares) as covariates.
| Units on a scale | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Hyperglycemia | -1.8 ± 0.12 | -2.1 ± 0.12 | -2.0 ± 0.12 | -1.3 ± 0.12 |
| Hypoglycemia | -1.9 ± 0.11 | -1.9 ± 0.12 | -2.0 ± 0.12 | -1.8 ± 0.12 |
| Treatment Satisfaction Score | 16.0 ± 0.27 | 15.8 ± 0.28 | 15.9 ± 0.29 | 14.2 ± 0.28 |
The hypoglycemia events were defined by participant reported events with blood glucose \< 54 mg/dL \[\<3.0 Millimole per Liter (mmol/L)\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of post-baseline hypoglycemia was estimated by negative binomial model: Number of episodes = Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment, with log (exposure in days/365.25) as an offset variable.
| Episodes/participant/365.25 days | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia | 0.0658 ± 0.02603 | 0.0890 ± 0.03196 | 0.0700 ± 0.02273 | 0.0538 ± 0.01594 |
Collected over Baseline Through End of Safety Follow-Up (Up To Week 44).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide | 0/230 (0%) | 15/230 (6.5%) | 174/230 (75.7%) |
| 10 mg Tirzepatide | 0/228 (0%) | 14/228 (6.1%) | 201/228 (88.2%) |
| 15 mg Tirzepatide | 1/229 (0.4%) | 15/229 (6.6%) | 193/229 (84.3%) |
| Insulin Glargine | 2/220 (0.9%) | 20/220 (9.1%) | 83/220 (37.7%) |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Cerebral infarctionNervous system disorders | 3/230 | 0/228 | 2/229 | 1/220 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/96 | 0/102 | 0/100 | 0/102 |
| Ovarian germ cell teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/96 | 0/102 | 1/100 | 0/102 |
| AdenomyosisReproductive system and breast disorders | 0/96 | 0/102 | 0/100 | 1/102 |
| VertigoEar and labyrinth disorders | 0/230 | 0/228 | 1/229 | 2/220 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/230 | 2/228 | 0/229 | 0/220 |
| Vertebrobasilar insufficiencyNervous system disorders | 0/230 | 0/228 | 2/229 | 1/220 |
| EpididymitisInfections and infestations | 0/134 | 0/126 | 0/129 | 1/118 |
| Atrial fibrillationCardiac disorders | 0/230 | 0/228 | 0/229 | 1/220 |
| Coronary artery diseaseCardiac disorders | 0/230 | 0/228 | 0/229 | 1/220 |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine |
|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 74/230 | 109/228 | 102/229 | 0/220 |
| DiarrhoeaGastrointestinal disorders | 77/230 | 103/228 | 101/229 | 3/220 |
| NauseaGastrointestinal disorders | 46/230 | 75/228 | 73/229 | 5/220 |
| VomitingGastrointestinal disorders | 21/230 | 34/228 | 29/229 | 3/220 |
| Abdominal distensionGastrointestinal disorders | 19/230 | 25/228 | 34/229 | 2/220 |
| Lipase increasedInvestigations | 32/230 | 32/228 | 30/229 | 6/220 |
| HyperuricaemiaMetabolism and nutrition disorders | 27/230 | 28/228 | 27/229 | 24/220 |
| DizzinessNervous system disorders | 10/230 | 13/228 | 24/229 | 10/220 |
| FlatulenceGastrointestinal disorders | 20/230 | 23/228 | 18/229 | 2/220 |
| FatigueGeneral disorders | 12/230 | 23/228 | 17/229 | 3/220 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine | Total |
|---|---|---|---|---|---|
| Mean | 53.10 ± 11.25 | 53.50 ± 11.14 | 54.30 ± 11.65 | 55.60 ± 11.40 | 54.10 ± 11.38 |
| Sex: Female, Male(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine | Total |
|---|---|---|---|---|---|
| Female | 96 | 102 | 100 | 102 | 400 |
| Male | 134 | 126 | 129 | 118 | 507 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 230 | 228 | 229 | 220 | 907 |
| Race (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 225 | 225 | 226 | 216 | 892 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 3 | 0 | 5 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 3 | 0 | 4 | 10 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine | Total |
|---|---|---|---|---|---|
| Australia | 5 | 3 | 3 | 4 | 15 |
| China | 190 | 192 | 190 | 184 | 756 |
| India | 9 | 7 | 9 | 7 | 32 |
| South Korea | 26 | 26 | 27 | 25 | 104 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Glargine | Total |
|---|---|---|---|---|---|
| Mean | 8.77 ± 0.976 | 8.70 ± 0.955 | 8.67 ± 0.960 | 8.68 ± 0.934 | 8.71 ± 0.956 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2019 to primary completion in Nov 2021, 22 months.
Results were first posted in Jan 2023, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide